Cutaneous responses in HER2+ metastatic breast cancer: A retrospective case series of a Phase 1b study of Tucatinib, an Oral HER2-specific inhibitor in combination with Capecitabine and/or Trastuzumab in third-line or later treatment
Cutaneous metastases are a common and very morbid development in women with metastatic breast cancer (MBC). Tucatinib, an oral, potent, HER2-specific reversible tyrosine kinase inhibitor, is a new treatment for HER2-positive MBC. Here, we describe a case series of 7 patients who had cutaneous metast...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621922000345 |